Stem cell showdown: donor vs. your own fat for Crohn's fistulas

NCT ID NCT05974280

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests two stem cell treatments for anal fistulas in people with Crohn's disease. One uses donor stem cells (Alofisel), the other uses stem cells from the patient's own fat. The goal is to see which works better at closing the fistula. The study plans to enroll 20 adults with complex anal fistulas.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cells (Alofisel or fat-derived stem cells)
What this could lead to: If successful, this could point toward a more affordable and effective treatment for anal fistulas in Crohn's disease, potentially using the patient's own fat cells.
What could go wrong: This is a very small pilot study with only 20 participants, so results may not apply to everyone. The high cost and complexity of Alofisel may limit its use, and the autologous fat approach is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL FISTULA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal fistula Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAL FISTULA CROHN DISEASE

Contacts and locations

Locations

CHU Nantes
RECRUITING

Nantes, Nantes, 44000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.